These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 10897592

  • 1. [Clinical effects of trandolapril in chronic glomerulonephritis patients with renal insufficiency].
    Yoshida A, Takeda A, Fukuda M, Toda S, Morozumi K.
    Nihon Jinzo Gakkai Shi; 2000 May; 42(4):333-7. PubMed ID: 10897592
    [Abstract] [Full Text] [Related]

  • 2. The effect of enalapril on proteinuria in patients with chronic glomerulonephritis and renal insufficiency.
    Yoshida A, Morozumi K, Takeda A, Koyama K, Ideura T, Ikeda M, Oikawa T.
    Nihon Jinzo Gakkai Shi; 1993 Nov; 35(11):1249-52. PubMed ID: 8139137
    [Abstract] [Full Text] [Related]

  • 3. [Polymorphism studies of angiotensin converting enzyme gene in chronic glomerulonephritis].
    Kutyrina IM, Tareeva IE, Nosikov VV, Kamyshova ES, Gorashko NM, Chistiakov DA, Okonova EB, Troepol'skaia OV.
    Ter Arkh; 1999 Nov; 71(6):30-4. PubMed ID: 10420452
    [Abstract] [Full Text] [Related]

  • 4. Verapamil versus amlodipine in proteinuric non-diabetic nephropathies treated with trandolapril (VVANNTT study): design of a prospective randomized multicenter trial.
    Boero R, Rollino C, Massara C, Vagelli G, Gonella M, Berto IM, Bajardi P, Perosa P, Malcangi U, Giorgi MP, Ghezzi PM, Borzumati M, Baroni AM, Cogno C, Triolo G, Angelini D, Antonelli A, Quarello F.
    J Nephrol; 2001 Nov; 14(1):15-8. PubMed ID: 11281338
    [Abstract] [Full Text] [Related]

  • 5. Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up.
    Kanno Y, Okada H, Saruta T, Suzuki H.
    Clin Nephrol; 2000 Nov; 54(5):360-5. PubMed ID: 11105796
    [Abstract] [Full Text] [Related]

  • 6. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy.
    Stigant CE, Cohen J, Vivera M, Zaltzman JS.
    Am J Kidney Dis; 2000 Jan; 35(1):58-63. PubMed ID: 10620545
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to patients with chronic renal failure and healthy control subjects.
    Danielson B, Querin S, LaRochelle P, Sultan E, Mouren M, Bryce T, Stepniewski JP, Lenfant B.
    J Cardiovasc Pharmacol; 1994 Jan; 23 Suppl 4():S50-9. PubMed ID: 7527102
    [Abstract] [Full Text] [Related]

  • 8. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
    Matsuda H, Hayashi K, Saruta T.
    J Hum Hypertens; 2003 Apr; 17(4):271-6. PubMed ID: 12692572
    [Abstract] [Full Text] [Related]

  • 9. [Evaluation of trandolapril alone or in combination with a calcium channel blocker in hypertensive patients over 60 years of age].
    Gosse P, Vaur L, Dutrey-Dupagne C, Genes N, Destrée D, Elkik F.
    Ann Cardiol Angeiol (Paris); 1995 Nov; 44(9):517-24. PubMed ID: 8745662
    [Abstract] [Full Text] [Related]

  • 10. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL, Ekhlas A, Nguyen JM, Moranne O.
    Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
    [Abstract] [Full Text] [Related]

  • 11. Is the antiproteinuric response to inhibition of the renin-angiotensin system less effective during the night?
    Buter H, Hemmelder MH, van Paassen P, Navis G, de Zeeuw D, de Jong PE.
    Nephrol Dial Transplant; 1997 Jul; 12 Suppl 2():53-6. PubMed ID: 9269701
    [Abstract] [Full Text] [Related]

  • 12. [Suppressive effect of angiotensin converting enzyme inhibitor (ACEI) on the progression of renal insufficiency: a propensity score analysis].
    Hirabayashi A, Ogawa T, Urashima M, Sone M, Nihei H.
    Nihon Jinzo Gakkai Shi; 2004 Jan; 46(1):35-42. PubMed ID: 15007909
    [Abstract] [Full Text] [Related]

  • 13. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
    Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Sekizuka K, Ebihara I, Koide H.
    Am J Nephrol; 2000 Jan; 20(5):373-9. PubMed ID: 11092994
    [Abstract] [Full Text] [Related]

  • 14. [Experience in the use of valsartan with the aim to inhibit progression of kidney failure in patients with chronic glomerulonephritis].
    Shvetsov MIu, Medvedeva TIu, Kozlovskaia NL, Miroshnichenko NG, Okonova EB, Shonichev DG, Rudenko TE, Stavrovskaia EV, Plieva OK.
    Ter Arkh; 2001 Jan; 73(6):55-61. PubMed ID: 11521525
    [Abstract] [Full Text] [Related]

  • 15. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
    Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF.
    J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
    [Abstract] [Full Text] [Related]

  • 16. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial.
    Solomon SD, Rice MM, A Jablonski K, Jose P, Domanski M, Sabatine M, Gersh BJ, Rouleau J, Pfeffer MA, Braunwald E, Prevention of Events with ACE inhibition (PEACE) Investigators.
    Circulation; 2006 Jul 04; 114(1):26-31. PubMed ID: 16801465
    [Abstract] [Full Text] [Related]

  • 17. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
    Ozturk S, Sar F, Bengi-Bozkurt O, Kazancioglu R.
    Kidney Blood Press Res; 2009 Jul 04; 32(4):268-75. PubMed ID: 19776644
    [Abstract] [Full Text] [Related]

  • 18. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial.
    Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G, BENEDICT Study Group.
    J Am Soc Nephrol; 2006 Dec 04; 17(12):3472-81. PubMed ID: 17082240
    [Abstract] [Full Text] [Related]

  • 19. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
    Esnault VL, Brown EA, Apetrei E, Bagon J, Calvo C, DeChatel R, Holdaas H, Krcmery S, Kobalava Z, Amlodipine Versus Enalapril in Renal failure (AVER) Study Group.
    Clin Ther; 2008 Mar 04; 30(3):482-98. PubMed ID: 18405787
    [Abstract] [Full Text] [Related]

  • 20. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
    Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A, Sugisaki T, Suzuki H, Umemura S, Kawaguchi Y, Uchida S, Kuwahara M, Yamazaki T, Japanese Lasartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators.
    Clin Exp Nephrol; 2003 Sep 04; 7(3):221-30. PubMed ID: 14586719
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.